Teva Pharmaceutical Industries Limited (TLV:TEVA)
5,227.00
-73.00 (-1.38%)
Apr 24, 2025, 5:24 PM IDT
Teva Pharmaceutical Industries Employees
As of December 31, 2024, Teva Pharmaceutical Industries had 35,686 total employees, including 33,892 full-time and 1,794 part-time employees. The number of employees decreased by 786 or -2.16% compared to the previous year.
Employees
35,686
Change (1Y)
-786
Growth (1Y)
-2.16%
Revenue / Employee
1.73M ILS
Profits / Employee
-171.60K ILS
Market Cap
61.20B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 35,686 | -786 | -2.16% |
Dec 31, 2023 | 36,472 | 1,347 | 3.83% |
Dec 31, 2022 | 35,125 | -854 | -2.37% |
Dec 31, 2021 | 35,979 | -2,393 | -6.24% |
Dec 31, 2020 | 38,372 | -1,667 | -4.16% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Danel (Adir Yeoshua) | 3,961 |
Kamada | 420 |
Bait Bakfar | 228 |
Novolog (Pharm-Up 1966) | 955 |
Ilex Medical | 223 |
BrainsWay | 134 |
SofWave Medical | 126 |
InterCure | 270 |
Teva Pharmaceutical Industries News
- 15 days ago - Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out - Seeking Alpha
- 17 days ago - Teva, Samsung Bioepis launch biosimilar against AstraZeneca’s Soliris - Seeking Alpha
- 17 days ago - Teva filing for label expansion of migraine therapy Ajovy undergoes FDA review - Seeking Alpha
- 17 days ago - Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention - GlobeNewsWire
- 24 days ago - New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable - Financial Post
- 24 days ago - New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable - GlobeNewsWire
- 4 weeks ago - Teva Releases Q1 2025 Aide Memoire - Benzinga
- 4 weeks ago - Teva Releases Q1 2025 Aide Memoire - GlobeNewsWire